No hantavirus vaccine candidate has advanced beyond early-phase clinical testing or preclinical development, leaving no realistic pathway for regulatory approval by the end of 2026. Multiple research teams, including those at the US Army Medical Research Institute of Infectious Diseases and collaborations involving Moderna, have completed small Phase 1 trials or animal studies showing neutralizing antibody responses against strains such as Andes virus, yet none have reached the large-scale efficacy trials required for licensure. The virus’s low incidence and sporadic geographic distribution further complicate Phase 3 design, while standard regulatory timelines—even with accelerated pathways—extend well beyond the current year. Recent 2026 outbreaks have heightened scientific interest and funding discussions, but they have not altered the fundamental development timeline.